Developing the next generation in cancer diagnostics.
Liv Diagnostics is developing a new unique product to measure the migration behavior of tumor cells, which provides a predictive indicator of metastasis. This information is critical because metastasis causes 90% of all deaths in cancer1. Our product CellRACE provides direct and quantified information on the risk of metastasis by analyzing the migration behavior of living cells.
The initial development work has been focused on developing a prototype for diagnosing migratory breast cancer cells. We have obtained promising results in measuring of the migration capacity of different types of breast cancer cells.
The company has chosen to focus on diagnosis of tumor cells in breast cancer, but estimates that there are good opportunities for the product in other cancer forms. Research and development are conducted by Liv Diagnostics AB at the AstraZeneca BioVentureHub in Gothenburg, Sweden.
1) Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006 Jun;6(6):449-58.WHO/Cancerfonden